Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

96700/819 Attorney Docket No. Ganjam V. Kalpana First Inventor NHIBITION OF HIV-1 VIRION PRODUCTION BY A TRANSDOMINANT MUTANT OF INTERGRASE...

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. EV 335775543 US						<u>us</u>		
APPLICATION ELEMENTS			ADDRESS TO: Commissioner for Patents Mail Stop Patent Application					
See MPEP chapter 600 concerning utility patent application contents.			Ale	xandria, V	A 223	13-1450		
2. Submit an original and a Applicant claims: See 37 CFR 1.27 3. Specification (preferred errangemer - Descriptive title - Cross Reference - Statement Reg	[Total Pages 80]	(<i>if</i> a. [Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or					
or a computer program listing appendix			i i.					
	 Background of the Invention Brief Summary of the Invention 			c. Statements verifying identity of above copies				
 Brief Description of the Drawings (if filed) 			ACCOMPANYING APPLICATION PARTS					
 Detailed Description Claim(s) Abstract of the Disclosure 			9. Assignment Papers (cover sheet & document(s)) 37 CFR 3.73(b) Statement Power of Attorney					
Drowing(a) (25 11 S.C. 112) Total Shoots 10			(when there is an assignee) Attorney 11. English Translation Document (if applicable)					
 Drawing(s) (35 to 5). Oath or Declaration 	J.S.C. 113) [Total Sheets Total Pages] 11. [Information Disclosure Copies of IDS					
a. Newly executed (original or copy)			13. Preliminary Amendment					
Copy from a prior application (37 CFR 1.63 (d)) b. (for continuation/divisional with Box 18 completed)			14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
i. DELETION OF INVENTOR(S)			15. Certified Copy of Priority Document(s) (if foreign priority is claimed)					
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).			16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.					
6. Application Data Sheet. See 37 CFR 1.76			17. Other: Cover Letter					
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,								
or in an Application Data Sheet under 37 CFR 1.76:								
Continuation Divisional Continuation-in-part (CIP) of prior application No.:/								
Prior application information: Examiner Group Art Unit:								
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.								
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS								
- In the state of								
Customer Number or Bar Code Label (Insert Customer No. or Attach ber code label here) Or Correspondence address below								
Names	Alan D. Miller							
	Amster, Rothstein & Ebenstein							
Address	90 Park Avenue							
City	New York	State	New York	Zip Code		10016		
Country	USA	Telephone	(212) 697-5995	Fá	ax .	(212) 286-0854		
Name (Print/Type)	Alan D. Miller	Reg	y/Agent) 42,889					
Signature Will Month				Date	July	/ 21, 2003		
<u> </u>								

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450,Mail Stop Patent Application, Alexandria, VA 22313-1450.



AMSTER, ROTHSTEIN & EBENSTEIN

MORTON AMSTER
JESSE ROTHSTEIN (1934-2003)
DANIEL S. EBENSTEIN
PHILIP H. GOTTFRIED
MICHAEL J. BERGER
NEIL M. ZIPKIN
ANTHONY F. LO CICERO
KENNETH P. GEORGE
ABRAHAM KASDAN, PH.D.
IRA F. SILFIN IRA E. SILFIN CHESTER ROTHSTEIN

SENIOR COUNSEL CHARLES R. MACEDO MARK J. ROSENBERG KENNETH M. BERNSTEIN

OF COUNSEL JERRY D. DAINOW

CRAIG J. ARNOLD

ATTORNEYS AT LAW

PATENTS . TRADEMARKS . COPYRIGHTS

90 PARK AVENUE NEW YORK, NEW YORK 10016

TELEPHONE: (212) 697-5995 FACSIMILE: (212) 286-0854 NEAL L. ROSENBERG DENISE A. LINDENAUER RICHARD S. MANDARO NANCY M. DODDERIDGE NATALIE BOGDANOS PATRICK BOLAND* TREBOR LLOYD JOSEPH M. CASINO JOHN S. ECONOMOU MICHAEL V. SOLOMITA HOLLY PEKOWSKY MICHAEL P. KENNEY MARION P. METELSKI* MAX VERN DANA R. METES

BRIAN A. COMACK MARC J. JASON ELIE H. GENDLOFF, PH.D. DAVID MITNICK CHARLES W. RATH BERNARD MAISTER, M.D.* DAVID A. BOAG KAREN J. BERNSTEIN MATTHIEU HAUSIG JUNG HAHM REIKO KAJI ALAN MILLER, PH.D.

*NOT ADMITTED IN NEW YORK

KARL J. KOLBINGER

July 21, 2003

via Express Mail

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Mail Stop Patent Application

"Express Mail" mailing label No. EV 335775543 US

Date of Deposit: July 21, 2003 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450. Name: Alan D. Mitter

Signature:

Re: New U.S. Utility Patent Application

INHIBITION OF HIV-1 VIRION PRODUCTION BY A Title:

TRANSDOMINANT MUTANT OF INTEGRASE

INTERACTOR 1 (INI1)/hSNF5

Inventor: Ganjam V. Kalpana

Our File: 96700/819

Dear Sir:

Enclosed please find the following documents for filing with the aboveidentified utility patent application in the name of Ganjam V. Kalpana, entitled, INHIBITION OF HIV-1 VIRION PRODUCTION BY A TRANSDOMINANT MUTANT OF INTEGRASE INTERACTOR 1 (INI1)/hSNF5, claiming the benefit of U.S. Provisional Application No. 60/397,305, comprising the following:

- 1. Utility Patent Application Transmittal (Form (PTO/SB/05) (1 page);
- 2. Specification (69 pages), Claims (10 pages), Abstract (1page), and Figures 1-9 (10 Sheets); and
- 3. Return Receipt Postcard.

Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Commissioner for Patents

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN Attorneys for Applicant 90 Park Avenue New York, New York 10016 (212) 697-5995

Dated: July 21, 2003

New York, New York

By:

Registration No. 42,889